Omkostningseffektivitet ved behandling af type 1-diabetes med insulinpumpe
Overlæge Kirsten Nørgaard, MPolSc Anna Sohlberg & læge Gordan Goodall
Hvidovre Hospital, Endokrinologisk Afdeling, Medtronic AB, Järfälla, Sverige, og IMS Health AG, Allschwil/Basel, Schweiz
Cost-effectiveness of continuous subcutaneous insulin infusion therapy for type 1 diabetes
Ugeskr Læger 2010;172(27):2020-2025
This study's aim was to project the long-term clinical and economic outcomes of continuous subcutaneous insulin infusion (CSII) treatment compared to multiple daily injections (MDI) in type 1 diabetes patients in Denmark.
Material and methods:
The CORE diabetes model was used to project life expectancy, quality-adjusted life expectancy, cumulative incidence of diabetes-related complications and costs over patient lifetimes. The simulated cohort was based upon a recent meta-analysis of CSII treatment from over 50 studies. Direct and indirect costs (human capital approach) from a healthcare payer perspective were accounted in year 2005 local currency. Outcomes were discounted according to recommendations and simulations performed over a 60 year time horizon.
CSII treatment was associated with improved life expectancy, quality-adjusted life expectancy and reduced incidence of most diabetes-related complications compared to MDI. In the base case analysis, lifetime costs were higher for CSII than for MDI with incremental cost-effectiveness ratios in terms of cost per quality-adjusted life year gained within the range generally considered good value for money. Sensitivity analyses revealed that the findings were most sensitive to variation in assumptions regarding time horizon and hypoglycaemic event rate.
CSII led to improved long-term clinical outcomes due to improved glycaemic control versus MDI. Evaluation of the economic impact of CSII treatment versus MDI demonstrated that it would be likely to represent good value for money by currently accepted standards.